Modified HCV peptide immunogens

Details Modified HCV peptide immunogens Modified HCV peptide immunogens

2008-03-11

2008-03-11

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S185100, C424S186100, C424S204100, C424S228100, C435S320100, C536S023720

Reexamination Certificate

active

07341726

ABSTRACT:
Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

REFERENCES:
patent: 5709995 (1998-01-01), Chisari et al.
patent: 2005/0222069 (2005-10-01), Punnonen et al.
patent: WO 95/12677 (1995-05-01), None
patent: WO 95/27733 (1995-10-01), None
patent: WO 97/41440 (1997-11-01), None
Cerny et al. “Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif,” Journal of Clinical Investigation, vol. 95 No. 2, pp. 521-530 (Feb. 1995).
Lauer et al., “Vaccine-induced T-cell responses against HCV: one step taken, more to follow,” Gastroenterology, vol. 132 No. 4, pp. 1626-1628 (Apr. 2007).
Leroux-Roels, “Development of prophylactic and therapeutic vaccines against hepatitis C virus,” Expert Reviews of Vaccines, vol. 4 No. 3, pp. 351-371 (Jun. 2005).
Ahlers et al. “Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence,”Proc. Natl. Acad. Sci. USA, 94:10856-10861 (Sep. 1997).
Chang, et al., “Immunological Significance of Cytotoxic T Lymphocyte Epitope Variants in Patients Chronically Infected by the Hepatitis C Virus,”Journal of Clin Invest, 100(9):2376-2385 (1997).
Hudrisier et al., “Relative Implication of Peptide Residues in Binding to Major Histocompatibility Complex Class I H-2Db: Application to the Design of High-Affinity, Allele-Specific Peptides,”Molecular Immunology32:895-907 (1995).
Kalams et al., “T Cell Receptor Usage and Fine Specificity of Human Immunodeficiency Virus I—specific Cytotoxic T Lymphocyte Clones,”Journal of Experimental Medicine183:1669-1679 (1996).
Parker et al., “Sequence motifs important for peptide binding to the human MHC class I molecule HLA—A2,”The Journal of Immunology149:3580-3587 (1992).
Sarobe et al. “Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions,”J. Clin. Invest., 102(6):1239-1248 (Sep. 1998).
Shirai et al. “CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1,”J. Immund., 154(6):2733-2742 (Mar. 1995).

Affiliated with

Also associated with

Rating

Modified HCV peptide immunogens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified HCV peptide immunogens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified HCV peptide immunogens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2786645